Evidence map›Paper›PMID 40868933›Full record

ArticleLife (Basel, Switzerland)2025

Role of

Sarah Allegra, Giuliana Abbadessa, Francesco Chiara, Daniela Di Grazia, Cristina Mirabella, Maura Caudana, Marina Zanatta, Jenni Bertello, Vincenzo Voi, Silvia De Francia

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genetics and Genomics in Sickle Cell Disease in Africa.American journal of hematology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah AllegraClinical Pharmacology, Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy.ORCID 0000-0003-4933-0011
Giuliana AbbadessaClinical Pharmacology, Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy.ORCID 0000-0003-2727-2519
Francesco ChiaraClinical Pharmacology, Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy.ORCID 0000-0003-2585-9607
Daniela Di GraziaClinical Pharmacology, Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy.ORCID 0009-0007-1869-6762
Cristina MirabellaClinical Pharmacology, Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy.
Maura CaudanaClinical Pharmacology, Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy.
Marina ZanattaDepartment of Economics and Statistics "Cognetti de Martiis", University of Turin, 10124 Turin, Italy.ORCID 0009-0007-9808-2049
Jenni BertelloReference Centre for Haemoglobinopathies, Department of Clinical and Biological Sciences, University of Turin, 10124 Turin, Italy.
Vincenzo VoiReference Centre for Haemoglobinopathies, Department of Clinical and Biological Sciences, University of Turin, 10124 Turin, Italy.ORCID 0000-0001-7249-2735
Silvia De FranciaClinical Pharmacology, Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy.ORCID 0000-0002-9841-7802

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHydroxyurea is approved for the treatment of paediatric and adult sickle cell disease patients. It causes the synthesis of foetal haemoglobin and decreases platelets and granulocytes, but with a high interindividual variability, requiring higher dosages and escalating toxicity. Hereditary variables should be investigated to personalise treatment. We evaluated the possible influences of

methodsWe conducted a retrospective analysis on 79 treated patients. The polymorphisms of

resultsSub-Saharan patients with the

conclusionsThe findings demonstrate for the first time how crucial it is to assess the pharmacogenetics of hydroxyurea by taking into account the two sexes in different groups. Additionally, the data were evaluated with consideration for ethnic groups and individually for adults and children. Pharmacogenetic studies could improve the clinical management of hydroxyurea.

Indexed as

hydroxycarbamideMAP3K5OCT1pharmacogenetics

Identifiers

PMID40868933
PMCPMC12387457

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.